📊 ENTA Key Takeaways
Is Enanta Pharmaceuticals Inc. (ENTA) a Good Investment?
Enanta Pharmaceuticals faces severe operational challenges with persistent unprofitability, negative free cash flow of -$11.8M, and deteriorating fundamentals despite maintaining a strong balance sheet. The company is burning cash at an unsustainable rate while revenues declined 3.4% YoY, indicating a lack of sustainable business model or revenue growth to offset operating losses.
Enanta Pharmaceuticals shows weak current operating fundamentals, with declining revenue, deeply negative operating and net margins, and negative free cash flow. However, the company still has a strong liquidity profile, minimal leverage, and a balance sheet that provides time to fund development and absorb losses. The core fundamental picture is mixed: financial health is solid, but profitability and growth quality remain weak.
Why Buy Enanta Pharmaceuticals Inc. Stock? ENTA Key Strengths
- Strong liquidity position with $37.4M cash and 4.44x current ratio providing runway for operations
- Low financial leverage with 0.02x debt-to-equity ratio and minimal long-term debt of $2.0M
- Reasonable asset base of $329.5M with stockholders' equity of $126.6M
- Very strong liquidity with 4.44x current and quick ratios
- Low financial leverage with debt/equity of 0.02x and only $2.00M in long-term debt
- Asset base and cash position provide near-term operating flexibility despite ongoing losses
ENTA Stock Risks: Enanta Pharmaceuticals Inc. Investment Risks
- Severe and deepening operational losses with -64.1% net margin and -60.5% operating margin
- Negative free cash flow of -$11.8M indicates company is consuming cash to fund operations, with only ~3.2 years of runway at current burn rate
- Revenue decline of 3.4% YoY combined with inability to achieve profitability suggests product portfolio challenges and lack of commercial traction
- Negative interest coverage ratio of -1.3x indicates inability to service debt from operations
- Revenue declined year over year while margins remain deeply negative
- Negative operating cash flow and free cash flow indicate the business is not self-funding
- Negative ROE, ROA, and weak interest coverage reflect poor underlying earnings quality
Key Metrics to Watch
- Operating cash flow trend and runway sustainability
- Revenue stabilization and growth trajectory by product line
- Path to profitability and timeline to positive operating income
- Cash burn rate and total cash depletion timeline
- Pipeline advancement and clinical trial progress for late-stage candidates
- Revenue growth and operating margin improvement
- Operating cash flow burn and cash balance trend
Enanta Pharmaceuticals Inc. (ENTA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.44x current ratio provides a solid financial cushion.
ENTA Profit Margin, ROE & Profitability Analysis
ENTA vs Healthcare Sector: How Enanta Pharmaceuticals Inc. Compares
How Enanta Pharmaceuticals Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Enanta Pharmaceuticals Inc. Stock Overvalued? ENTA Valuation Analysis 2026
Based on fundamental analysis, Enanta Pharmaceuticals Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Enanta Pharmaceuticals Inc. Balance Sheet: ENTA Debt, Cash & Liquidity
ENTA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Enanta Pharmaceuticals Inc.'s revenue has declined by 61% over the 5-year period, indicating business contraction. The most recent EPS of $-6.38 indicates the company is currently unprofitable.
ENTA Revenue Growth, EPS Growth & YoY Performance
ENTA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $17.0M | -$11.9M | $-0.42 |
| Q3 2025 | $18.0M | -$18.3M | $-0.85 |
| Q2 2025 | $14.9M | -$22.3M | $-1.06 |
| Q3 2024 | $18.0M | -$22.7M | $-1.07 |
| Q2 2024 | $17.1M | -$29.0M | $-1.47 |
| Q1 2024 | $17.0M | -$22.3M | $-1.05 |
| Q3 2023 | $18.9M | -$29.0M | $-1.53 |
| Q2 2023 | $17.8M | -$29.0M | $-1.63 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Enanta Pharmaceuticals Inc. Dividends, Buybacks & Capital Allocation
ENTA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Enanta Pharmaceuticals Inc. (CIK: 0001177648)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ENTA
What is the AI rating for ENTA?
Enanta Pharmaceuticals Inc. (ENTA) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (HOLD) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ENTA's key strengths?
Claude: Strong liquidity position with $37.4M cash and 4.44x current ratio providing runway for operations. Low financial leverage with 0.02x debt-to-equity ratio and minimal long-term debt of $2.0M. ChatGPT: Very strong liquidity with 4.44x current and quick ratios. Low financial leverage with debt/equity of 0.02x and only $2.00M in long-term debt.
What are the risks of investing in ENTA?
Claude: Severe and deepening operational losses with -64.1% net margin and -60.5% operating margin. Negative free cash flow of -$11.8M indicates company is consuming cash to fund operations, with only ~3.2 years of runway at current burn rate. ChatGPT: Revenue declined year over year while margins remain deeply negative. Negative operating cash flow and free cash flow indicate the business is not self-funding.
What is ENTA's revenue and growth?
Enanta Pharmaceuticals Inc. reported revenue of $18.6M.
Does ENTA pay dividends?
Enanta Pharmaceuticals Inc. does not currently pay dividends.
Where can I find ENTA SEC filings?
Official SEC filings for Enanta Pharmaceuticals Inc. (CIK: 0001177648) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ENTA's EPS?
Enanta Pharmaceuticals Inc. has a diluted EPS of $-0.42.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ENTA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Enanta Pharmaceuticals Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ENTA stock overvalued or undervalued?
Valuation metrics for ENTA: ROE of -9.4% (sector avg: 15%), net margin of -64.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ENTA stock in 2026?
Our dual AI analysis gives Enanta Pharmaceuticals Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ENTA's free cash flow?
Enanta Pharmaceuticals Inc.'s operating cash flow is $-11.7M, with capital expenditures of $143.0K. FCF margin is -63.6%.
How does ENTA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -64.1% (avg: 12%), ROE -9.4% (avg: 15%), current ratio 4.44 (avg: 2).